Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS135 in Pulmonary Arterial Hypertension
NCT06493461Phase 1Terminated
- Sponsor
- 35Pharma
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HS135 in pulmonary arterial hypertension (PAH), sponsored by 35Pharma. Primary endpoints: Adverse Events (AEs) up to 24 weeks, Change from Baseline in Physical Examination up to 24 weeks and 2 more. Started Oct 2024; status: terminated.
02
Drugs
HS135
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06493461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493461.